
What began as an urgent, industry-wide safety review of nitrosamine impurities has settled into a permanent feature of pharmaceutical quality management. The call-for-review deadlines have[…]

Cell and gene therapies are among the most promising — and most complex — medicines in development. Advanced therapy medicinal products follow a dedicated regulatory[…]

Every prescription pack in Europe now carries a unique code and a tamper-evident seal. For companies supplying Greece, the country’s late arrival to this system[…]

Pricing a medicine in Greece is not a negotiation in the usual sense — it is largely a calculation, driven by the prices of other[…]

The randomised controlled trial remains the gold standard — but it no longer stands alone. Real-world evidence is increasingly shaping both regulatory approval and reimbursement[…]

No batch of medicine reaches a patient in the EU until one named individual takes personal legal responsibility for it. Understanding the Qualified Person’s role[…]

For most new medicines, developing for adults is only part of the obligation. The Paediatric Investigation Plan determines what a company must do for children[…]

Since the start of 2025, there is only one way to run a clinical trial in the EU. The Clinical Trials Regulation and its portal,[…]

The In Vitro Diagnostic Regulation reshaped how diagnostics reach the EU market — and while transition deadlines have been extended, the conditions attached to them[…]

The Clinical Trials Regulation (EU) No 536/2014 has reshaped how trials are authorised across Europe. Since the three-year transition period closed on 31 January 2025,[…]